What is Maze Therapeutics Inc. Annual Net Profit?

Maze Therapeutics Inc. Annual Net Profit rose 152.02% in the last year to $52.23 M. Its sector's average net profit growth for the last fiscal year was -32.59%.

What is Maze Therapeutics Inc. Stock Price?

Maze Therapeutics Inc. Stock Price fell 13.67% underperformed its sector by 8.92% in the past week.

What is Maze Therapeutics Inc. Quarterly Net profit?

Maze Therapeutics Inc. Quarterly Net profit fell 11.3% YoY to $29.58 M. Its sector's average net profit growth YoY for the quarter was -47.22%.

What is Maze Therapeutics Inc. Mutual Fund Holding?

Maze Therapeutics Inc. Mutual Fund Holding increased by 5.32% in the last quarter to 5.32.

How is the Maze Therapeutics Inc. today?

The Maze Therapeutics Inc. today is trading in the green, up by 3.03% at 7.83.

How has Maze Therapeutics Inc. performed historically?

The Maze Therapeutics Inc. is currently trading up 3.03% on an intraday basis in the past week the index fell -13.67%. The index has been down None% in the past quarter and fell None% in the past year. You can view this in the overview section.

Maze Therapeutics Inc. XNAS: MAZE

Maze Therapeutics Inc. Live Share Price Today, Share Analysis and Chart

Name: Maze Therapeutics Inc.: Is Infosys Ltd. worth buying?
Item: Maze Therapeutics Inc.
Rating: 0.65941675
Author: Trendlyne DVM scores

Download real time

7.83 0.23 (3.03%)

New 52W Low in past week

236.8K XNAS Volume

XNAS 11 Apr, 2025 5:30 PM (EDT)

Maze Therapeutics Inc. Key Metrics

My Metrics

Default

Market Capitalization Below industry Median Unavailable in chosen country	342.9
Price to Book Negative Price to Book Unavailable in chosen country	-1.1
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-11.3
Piotroski Score Below industry Median Unavailable in chosen country	2

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

13.2 / 100

Technically Bearish

13.2 / 100

1Yr Price target upside is 228%

3 analysts

Check Before You Buy

Check P/E Buy Sell Zone

Not enough data available

Maze Therapeutics Inc. Stock Price Analysis

Day Price Range 3.0% 1 Day return Unavailable in chosen country	7.8 (LTP) 6.87.9 LowHigh
Week Price Range -13.7% 1 Week return Unavailable in chosen country	7.8 (LTP) 6.79.4 LowHigh
Month Price Range -30.2% 1 Month return Unavailable in chosen country	7.8 (LTP) 6.713 LowHigh

View full Share Price History

Maze Therapeutics Inc. Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

Maze Therapeutics Inc.'s Revenue was higher than average estimate 1 time in past 1 year

EPS forecast

QUARTER
ANNUAL

Current EPS

1.3

Avg. Estimate

-2.7

Low Estimate

-3.2

High Estimate

-2.3

Current EPS

Avg. Estimate

Miss

EPS is expected to reduce by 320.0% in FY25

Consensus Recommendation

4 ANALYST Recommendations

STRONG BUY

The consensus recommendation from 4 analysts for Maze Therapeutics Inc. is STRONG BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Competitors/Peers

Quarterly Results

Annual Results

Balance Sheet

Financial Ratios

Cash Flow

Maze Therapeutics Inc. - Quarterly Results

Maze Therapeutics Inc. quarterly, revenue, profit, P&L - 13 Quarters history

Nested row level

Base Level

Reported Types

Originally Reported

Settings

Column Order

New to Old

Cell Coloring

YoY

Nested row level

Base Level

Export

NEUTRAL
Quarterly Revenue Maze Therapeutics Inc. Dec-2024 Quarterly Revenue is $0 Million which is growth of 0% YoY.
NEGATIVE
Quarterly Net Profit Maze Therapeutics Inc. Dec-2024 Quarterly Net Profit is $-30 Million which is growth of -11.3% YoY.

* All financials are is in USD Million and price data in USD

Indicator	Dec '24	Sep '24	Jun '24	Dec '23	Sep '23
SR_Q Operating Rev.		2.5	-
CostOfRevenue_Q Cost Of Rev.	-	-	-	-	-
GrossProfit_Q Gross Profit	-	-	-	-	-
OEXPNS_Q Operating Exp.	29.7	26.7	-	23.1	25.2
AdminAndSellingExpenses_Q Admin Plus Selling Exp.	7.5	6.9	-	7	5.8
ResearchAndDevlopmentExpenses_Q RnD Exp.	22.2	19.9	-	16	19.5
OP_Q Operating Profit	-29.7	-24.2	-	-23.1	-25.2
NetNonOperIntIncExp_Q Net Non Operations Interest Incuding Expenses	1.5	1.9	-	0.3	0.5
Others_Q Other Interest Earned	1.5	1.9	-	0.3	0.5
IntExpNonOperating_Q Interest Exp. Non Operating	-	-	-	-	-
PBT_Q Profit Before Tax	-29.9	-25	-	-26.6	-24.8
TAX_Q Tax	-0.3	-0.3	-	-
NICommonStockholders_Q Net Income Common Stockholders	-4.9	-2.4	-	-26.6	-24.8
NP_Q Net Profit	-29.6	-24.8	-	-26.6	-24.8
NIIncludingNoncontrollingInterests_Q Net Income Including Non controlling Interests	-29.6	-24.8	-	-26.6	-24.8
DilutedNIAvailtoComStockholders_Q Diluted NI Avail to Com Stockholders Ann.	-5.6	-1.4	-	-26.6	-24.8
EPS_Q Basic EPS	-1	-0.1	-	-0.8	-0.7
AfterDilutedEPS_Q Diluted EPS After ExtraOrdinary	-1	-0.1	-	-0.8	-0.7
SHARE_Q Number Of Shares End	43.8	43.8	-	35	35
NIContinuingDiscontinuedOper_Q Net Income Continuing Discontinued Operations	-29.6	-24.8	-	-26.6	-24.8
NormalizedIncome_Q Normalized Income	-29.6	-24.8	-	-26.6	-24.8
InterestIncome_Q Interest Income	1.5	1.9	-	0.3	0.5
INT_Q Interest	-	-	-	-	-
NetInterestIncome_Q Net Interest Income	1.5	1.9	-	0.3	0.5
EBIT_Q EBIT	-29.7	-24.2	-	-23.1	-25.2
EBITDA_Q EBITDA	-29	-23.4	-	-22.1	-24.2
ReconciledCostOfRevenue_Q Reconciled Cost Of Rev.	-	-	-	-	-
ReconciledDepreciation_Q Reconciled Depr.	0.7	0.8	-	1	1
ProfitLossFromContinuingOperations_Q Profit From Continuing Operations	-29.6	-24.8	-	-26.6	-24.8
NormalizedEBITDA_Q Normalized EBITDA	-29	-23.4	-	-22.1	-24.2

*All financials are in $ Million

Add metric to table

Search...

Maze Therapeutics Inc. Stock Analysis

Maze Therapeutics Inc. stock analysis with key metrics, changes, and trends.

Maze Therapeutics Inc. Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$52.23 M	152.02%	positive	Annual Net Profit rose 152.02% in the last year to $52.23 M. Its sector's average net profit growth for the last fiscal year was -32.59%.
Stock Price	$7.83	-13.67%	negative	Stock Price fell 13.67% underperformed its sector by 8.92% in the past week.
Quarterly Net profit	$29.58 M	11.3%	negative	Quarterly Net profit fell 11.3% YoY to $29.58 M. Its sector's average net profit growth YoY for the quarter was -47.22%.
Mutual Fund Holding	5.32 %	5.32%	positive	Mutual Fund Holding increased by 5.32% in the last quarter to 5.32.

Loading data..

Maze Therapeutics Inc. - Company Profile

What does Maze Therapeutics Inc. do?

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

113.43 K

2024

Gross Remuneration

Year

Maze Therapeutics Inc. Live Share Price Today, Share Analysis and Chart

New 52W Low in past week

Maze Therapeutics Inc. Key Metrics

Market Capitalization

Price to Book

Net Profit Qtr Growth YoY %

Piotroski Score

Market Capitalization

Price to Book

Net Profit Qtr Growth YoY %

Piotroski Score

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Maze Therapeutics Inc. Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

Maze Therapeutics Inc. Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Maze Therapeutics Inc.'s Revenue was higher than average estimate 1 time in past 1 year

EPS forecast

EPS is expected to reduce by 320.0% in FY25

Consensus Recommendation

The consensus recommendation from 4 analysts for Maze Therapeutics Inc. is STRONG BUY

Maze Therapeutics Inc. - Quarterly Results

Maze Therapeutics Inc. quarterly, revenue, profit, P&L - 13 Quarters history

Quarterly Revenue Maze Therapeutics Inc. Dec-2024 Quarterly Revenue is $0 Million which is growth of 0% YoY.

Quarterly Net Profit Maze Therapeutics Inc. Dec-2024 Quarterly Net Profit is $-30 Million which is growth of -11.3% YoY.

Maze Therapeutics Inc. Stock Analysis

Maze Therapeutics Inc. stock analysis with key metrics, changes, and trends.

Annual Net Profit rose 152.02% in the last year to $52.23 M. Its sector's average net profit growth for the last fiscal year was -32.59%.

Stock Price fell 13.67% underperformed its sector by 8.92% in the past week.

Quarterly Net profit fell 11.3% YoY to $29.58 M. Its sector's average net profit growth YoY for the quarter was -47.22%.

Mutual Fund Holding increased by 5.32% in the last quarter to 5.32.

Maze Therapeutics Inc. - Company Profile

What does Maze Therapeutics Inc. do?

Maze Therapeutics Inc. Management structure

Dr. Jason V. Coloma, PhD

Chief Executive Officer and Director

Dr. Harold S. Bernstein

President, Research and Development and Chief Medical Officer

Ms. Courtney J. Phillips

General Counsel and Corporate Secretary

Mr. Atul Dandekar

Chief Strategy and Business Officer

Ms. Amy Bachrodt

Senior Vice Preisdent, Finance and Principal Accounting Officer

Maze Therapeutics Inc. Board of directors

Dr. Charles J. Homcy,M.D.

Chairman of the Board

Dr. Richard H. Scheller, PhD

Independent Director

Dr. Sekar Kathiresan, M.D.

Independent Director

Mr. Daniel K. Spiegelman

Independent Director

Dr. Catherine Angell Sohn, Pharm.D.

Independent Director

Dr. Nancy C. Andrews, M.D.,PhD

Independent Director

Maze Therapeutics Inc. FAQ

How is Maze Therapeutics Inc. today?

Maze Therapeutics Inc. today is trading in the green, and is up by 3.03% at 7.83.

How has Maze Therapeutics Inc. performed historically?

Maze Therapeutics Inc. is currently trading up 3.03% on an intraday basis. In the past week the stock fell -13.67%. stock has been down None% in the past quarter and fell None% in the past year. You can view this in the overview section.